Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Classical hematology 2Breast 1

Conditions

Breast Neoplasms 23Ovarian Neoplasms 18Neoplasm Metastasis 12Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Pancreatic Neoplasms 8Neoplasms 8Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma 2Lung Neoplasms 2Hodgkin Disease 2Fanconi Anemia, Complementation Group D1 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumours 2Advanced Solid Tumor 2Advanced Cancer 2Triple Negative Metastatic Breast Cancer 1Thymoma 1Thrombocytosis 1Solid Tumor 1

Interventions

olaparib 2talazoparib 1Carboplatin 1ABT-767 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Fanconi Anemia, Complementation Group D1 × olaparib × Clear all
NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

AstraZeneca

Phase 1 Completed
98 enrolled
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02418624 2019-01-16

REVIVAL

The Netherlands Cancer Institute

Phase 1 Completed
25 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡